<sup>18</sup>F-FDG Avidity in Lymphoma Readdressed: A Study of 766 Patients
Michal Weiler‐Sagie(Rambam Health Care Campus), Ora Israel(Technion – Israel Institute of Technology), Rachel Bar‐Shalom(Rambam Health Care Campus), Nissim Haim(Technion – Israel Institute of Technology), Eldad J. Dann(Rambam Health Care Campus), Olga Bushelev(Technion – Israel Institute of Technology), Ron Epelbaum(University of Bern), Irit Avivi(Tel Aviv Sourasky Medical Center), Yehudit Ben-Arie(Technion – Israel Institute of Technology), Ayelet Ben‐Barak(Rambam Health Care Campus)
Cited by 381
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Curcumin as an Anti-Cancer Agent: Review of the Gap Between Basic and Clinical Applications
|Current Medicinal Chemistry|2009|480
Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers
|British Journal of Cancer|2014|444
Curcumin and Gemcitabine in Patients With Advanced Pancreatic Cancer
|Nutrition and Cancer|2010|279